Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
NCT01155713
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
63
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasm
Cancer
Tumors
Interventions
DRUG:
TKI258
Sponsor
Novartis Pharmaceuticals